Molecular Imaging and Biology

, Volume 14, Issue 5, pp 584–592

In Vivo Quantification of Tumor Receptor Binding Potential with Dual-Reporter Molecular Imaging

Authors

    • Thayer School of EngineeringDartmouth College
  • Kimberley S. Samkoe
    • Thayer School of EngineeringDartmouth College
    • Department of SurgeryDartmouth Medical School
  • Kristian J. Sexton
    • Thayer School of EngineeringDartmouth College
  • Shannon K. Hextrum
    • Thayer School of EngineeringDartmouth College
  • Harold H. Yang
    • Thayer School of EngineeringDartmouth College
  • W. Spencer Klubben
    • Thayer School of EngineeringDartmouth College
  • Jason R. Gunn
    • Thayer School of EngineeringDartmouth College
  • Tayyaba Hasan
    • Wellman Center for PhotomedicineMassachusetts General Hospital
    • Thayer School of EngineeringDartmouth College
    • Department of SurgeryDartmouth Medical School
    • Wellman Center for PhotomedicineMassachusetts General Hospital
Research Article

DOI: 10.1007/s11307-011-0534-y

Cite this article as:
Tichauer, K.M., Samkoe, K.S., Sexton, K.J. et al. Mol Imaging Biol (2012) 14: 584. doi:10.1007/s11307-011-0534-y

Abstract

Purpose

Receptor availability represents a key component of current cancer management. However, no approaches have been adopted to do this clinically, and the current standard of care is invasive tissue biopsy. A dual-reporter methodology capable of quantifying available receptor binding potential of tumors in vivo within a clinically relevant time scale is presented.

Procedures

To test the methodology, a fluorescence imaging-based adaptation was validated against ex vivo and in vitro measures of epidermal growth factor receptor (EGFR) binding potential in four tumor lines in mice, each line expected to express a different level of EGFR.

Results

A strong correlation was observed between in vivo and ex vivo measures of binding potential for all tumor lines (r = 0.99, p < 0.01, slope = 1.80 ± 0.48, and intercept = −0.58 ± 0.84) and between in vivo and in vitro for the three lines expressing the least amount of EGFR (r = 0.99, p < 0.01, slope = 0.64 ± 0.32, and intercept = 0.47 ± 0.51).

Conclusions

By providing a fast and robust measure of receptor density in tumors, the presented methodology has powerful implications for improving choices in cancer intervention, evaluation, and monitoring, and can be scaled to the clinic with an imaging modality like SPECT.

Key words

Molecular imagingFluorescenceTargeted reporterEpidermal growth factor receptorMouse model

Copyright information

© World Molecular Imaging Society 2011